



US009409989B2

(12) **United States Patent**
Arathoon et al.

(10) **Patent No.:** **US 9,409,989 B2**
(45) **Date of Patent:** ***Aug. 9, 2016**

(54) **METHOD FOR MAKING MULTISPECIFIC ANTIBODIES HAVING HETEROMULTIMERIC AND COMMON COMPONENTS**

(71) Applicant: **GENENTECH, INC.**, South San Francisco, CA (US)
(72) Inventors: **W. Robert Arathoon**, San Mateo, CA (US); **Paul J. Carter**, Seattle, WA (US); **Anne M. Merchant**, Redwood City, CA (US); **Leonard G. Presta**, San Francisco, CA (US)

(73) Assignee: **Genetech, Inc.**, South San Francisco, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 151 days.
This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/142,663**

(22) Filed: **Dec. 27, 2013**

(65) **Prior Publication Data**

US 2014/0322756 A1 Oct. 30, 2014

Related U.S. Application Data

(63) Continuation of application No. 11/608,673, filed on Dec. 8, 2006, now Pat. No. 8,642,745, which is a continuation of application No. 09/520,130, filed on Mar. 7, 2000, now Pat. No. 7,951,917, which is a continuation of application No. 09/070,416, filed on Apr. 30, 1998, now abandoned.

(60) Provisional application No. 60/050,661, filed on Jun. 24, 1997, provisional application No. 60/046,816, filed on May 2, 1997.

(51) **Int. Cl.**

C07H 21/02 (2006.01)
C07H 21/04 (2006.01)
C12N 5/10 (2006.01)
C12N 15/09 (2006.01)
C12N 15/13 (2006.01)
C12N 15/63 (2006.01)
C07K 16/46 (2006.01)
C07K 16/28 (2006.01)
C07K 1/22 (2006.01)
A61K 38/00 (2006.01)

(52) **U.S. Cl.**

CPC **C07K 16/2863** (2013.01); **C07K 1/22** (2013.01); **C07K 16/2809** (2013.01); **C07K 16/2812** (2013.01); **C07K 16/46** (2013.01); **C07K 16/468** (2013.01); **A61K 38/00** (2013.01); **C07K 2317/732** (2013.01); **Y10S 435/972** (2013.01)

(58) **Field of Classification Search**

CPC C12N 5/0682; C12N 5/116; C12N 5/12; C12N 15/09; C12N 15/63; C12N 15/85; C07H 21/02; C07H 21/04; C07K 16/468

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,816,567 A 3/1989 Cabbily et al.
5,116,964 A 5/1992 Capon et al.
5,591,828 A 1/1997 Bosslet et al.
5,731,168 A 3/1998 Carter et al.
5,807,706 A 9/1998 Carter et al.
5,821,333 A 10/1998 Carter et al.
6,515,110 B1 2/2003 Whitlow et al.
7,183,076 B2* 2/2007 Arathoon C07K 16/00 435/328
7,262,028 B2 8/2007 Van Berkel et al.
7,642,228 B2 1/2010 Carter et al.
7,695,937 B2 4/2010 Baum
8,216,805 B2 7/2012 Carter et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP 314317 A1 5/1989
WO 89/02922 A1 4/1989

(Continued)

OTHER PUBLICATIONS

Yang, Y.-B., et al., Journal of Chromatography A., 743: 171-180, 1996.*

Le Doussal et al., "Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response," J. Nucl. Med. 34 (10)1662-1671 (1993).

Le Doussal et al., "Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: theoretical, experimental and clinical results," Int. J. Cancer Suppl. 7:58-62 (1992).

Lou et al., "VI-linker-Vh orientation-dependent expression of single chain Fv-containing an engineered disulfide-stabilized bond in the framework regions," J. Biochem. 118(4):825-831 (1995).

(Continued)

Primary Examiner — Alana Harris Dent

Assistant Examiner — Anne Holleran

(74) *Attorney, Agent, or Firm* — Jones Day

(57) **ABSTRACT**

The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide. The method allows for the enhanced formation of the desired heteromultimer relative to undesired heteromultimers and homomultimers.